408 related articles for article (PubMed ID: 27490453)
1. Microbiome, trimethylamine N-oxide, and cardiometabolic disease.
Tang WH; Hazen SL
Transl Res; 2017 Jan; 179():108-115. PubMed ID: 27490453
[TBL] [Abstract][Full Text] [Related]
2. The gut microbiome, diet, and links to cardiometabolic and chronic disorders.
Aron-Wisnewsky J; Clément K
Nat Rev Nephrol; 2016 Mar; 12(3):169-81. PubMed ID: 26616538
[TBL] [Abstract][Full Text] [Related]
3. Targeting the human microbiome and its metabolite TMAO in cardiovascular prevention and therapy.
Dannenberg L; Zikeli D; Benkhoff M; Ahlbrecht S; Kelm M; Levkau B; Polzin A
Pharmacol Ther; 2020 Sep; 213():107584. PubMed ID: 32446759
[TBL] [Abstract][Full Text] [Related]
4. Listening to Our Gut: Contribution of Gut Microbiota and Cardiovascular Risk in Diabetes Pathogenesis.
Li D; Kirsop J; Tang WH
Curr Diab Rep; 2015 Sep; 15(9):63. PubMed ID: 26208694
[TBL] [Abstract][Full Text] [Related]
5. Gut Microbiota and Atherosclerosis.
Li DY; Tang WHW
Curr Atheroscler Rep; 2017 Aug; 19(10):39. PubMed ID: 28842845
[TBL] [Abstract][Full Text] [Related]
6. Diagnostics and therapeutic implications of gut microbiota alterations in cardiometabolic diseases.
Schiattarella GG; Sannino A; Esposito G; Perrino C
Trends Cardiovasc Med; 2019 Apr; 29(3):141-147. PubMed ID: 30126689
[TBL] [Abstract][Full Text] [Related]
7. Interaction between gut microbiome and cardiovascular disease.
Peng J; Xiao X; Hu M; Zhang X
Life Sci; 2018 Dec; 214():153-157. PubMed ID: 30385177
[TBL] [Abstract][Full Text] [Related]
8. Exploring the Microbiome in Heart Failure.
Kitai T; Kirsop J; Tang WH
Curr Heart Fail Rep; 2016 Apr; 13(2):103-9. PubMed ID: 26886380
[TBL] [Abstract][Full Text] [Related]
9. Gut Microbiota and Cardiovascular Disease.
Witkowski M; Weeks TL; Hazen SL
Circ Res; 2020 Jul; 127(4):553-570. PubMed ID: 32762536
[TBL] [Abstract][Full Text] [Related]
10. Trimethylamine
Canyelles M; Tondo M; Cedó L; Farràs M; Escolà-Gil JC; Blanco-Vaca F
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347638
[TBL] [Abstract][Full Text] [Related]
11. Gut microbiota-associated trimethylamine N-oxide and increased cardiometabolic risk in adults: a systematic review and dose-response meta-analysis.
Abbasalizad Farhangi M; Vajdi M
Nutr Rev; 2021 Aug; 79(9):1022-1042. PubMed ID: 33270896
[TBL] [Abstract][Full Text] [Related]
12. Gut microbiota metabolism of L-carnitine and cardiovascular risk.
Ussher JR; Lopaschuk GD; Arduini A
Atherosclerosis; 2013 Dec; 231(2):456-61. PubMed ID: 24267266
[TBL] [Abstract][Full Text] [Related]
13. TMAO: how gut microbiota contributes to heart failure.
Zhang Y; Wang Y; Ke B; Du J
Transl Res; 2021 Feb; 228():109-125. PubMed ID: 32841736
[TBL] [Abstract][Full Text] [Related]
14. The human gut microbiome - a new and exciting avenue in cardiovascular drug discovery.
Du Y; Li X; Su C; Wang L; Jiang J; Hong B
Expert Opin Drug Discov; 2019 Oct; 14(10):1037-1052. PubMed ID: 31315489
[No Abstract] [Full Text] [Related]
15. Trimethylamine N-oxide (TMAO) as a New Potential Therapeutic Target for Insulin Resistance and Cancer.
Oellgaard J; Winther SA; Hansen TS; Rossing P; von Scholten BJ
Curr Pharm Des; 2017; 23(25):3699-3712. PubMed ID: 28641532
[TBL] [Abstract][Full Text] [Related]
16. Trimethylamine-N-oxide (TMAO) response to animal source foods varies among healthy young men and is influenced by their gut microbiota composition: A randomized controlled trial.
Cho CE; Taesuwan S; Malysheva OV; Bender E; Tulchinsky NF; Yan J; Sutter JL; Caudill MA
Mol Nutr Food Res; 2017 Jan; 61(1):. PubMed ID: 27377678
[TBL] [Abstract][Full Text] [Related]
17. Trimethylamine N-oxide in cardiovascular disease.
Konieczny RA; Kuliczkowski W
Adv Clin Exp Med; 2022 Aug; 31(8):913-925. PubMed ID: 35438848
[TBL] [Abstract][Full Text] [Related]
18. Gut microbiota in atherosclerosis: focus on trimethylamine N-oxide.
Zhu Y; Li Q; Jiang H
APMIS; 2020 May; 128(5):353-366. PubMed ID: 32108960
[TBL] [Abstract][Full Text] [Related]
19. The Role of Microbiota in Cardiovascular Risk: Focus on Trimethylamine Oxide.
Al-Rubaye H; Perfetti G; Kaski JC
Curr Probl Cardiol; 2019 Jun; 44(6):182-196. PubMed ID: 30482503
[TBL] [Abstract][Full Text] [Related]
20. Human microbiome as therapeutic intervention target to reduce cardiovascular disease risk.
Koopen AM; Groen AK; Nieuwdorp M
Curr Opin Lipidol; 2016 Dec; 27(6):615-622. PubMed ID: 27676197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
